Monotherapy 15 or 30 mg. Combination therapy 15 or 30 mg w/ current sulphonylurea, metformin or insulin dose. Max: 45 mg. All doses to be given once daily.
Administration
May be taken with or without food.
Contraindications
NYHA class III or IV heart failure.
Special Precautions
Type 1 diabetes, diabetic ketoacidosis. CHF, symptomatic heart failure, edema, macular edema. Increase incidence of bone fracture especially in women. Ovulation may occur in premenopausal anovulatory women. Periodic monitoring of liver enzymes. Evaluate serum ALT levels prior to initiation of therapy & periodically thereafter. Reduce dose of concomitant antidiabetic therapy if hypoglycemia occurs. Monitor for fluid retention-related adverse events. Childn <18 yr.
Adverse Reactions
URTI, headache, sinusitis, myalgia, tooth disorder, aggravated DM, pharyngitis. Mild to moderate hypoglycemia during combination therapy. Anemia, edema, macular edema, CV events, decreases in Hb & hematocrit, wt gain, reversible elevation in ALT & CPK.
Sign Out
